Purpose: To investigate whether allogeneic stem-cell transplantation (allo-SCT) may overcome the negative impact of unmutated VH genes in the outcome of patients with chronic lymphocytic leukemia (CLL).
Patients And Methods: We analyzed the outcome of patients who underwent SCT according to their VH mutational status.
Results: Thirty-four patients (14 allo-SCT and 20 autologous SCT [auto-SCT]) presented unmutated VH genes and 16 patients presented mutated VH genes (nine allo-SCT and seven auto-SCT). Tumoral burden pre-SCT was significantly higher in the allo-SCT patients independent of the VH mutational status. The risk of relapse was significantly higher after auto-SCT (5-year risk, 61%; 95% CI, 44% to 84%) than after allo-SCT (5-year risk 12%, 95% CI, 3% to 44%; P < .05). In the unmutated group, 13 of 20 auto-SCT and two of 14 allo-SCT patients experienced disease progression, with a risk of relapse at 5 years of 66% (95% CI, 48% to 93%) v 17% (95% CI, 5% to 60%), respectively (P = .01).
Conclusion: These results show that allo-SCT may overcome the unfavorable effect of unmutated VH genes in patients with CLL.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JCO.2005.04.531 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The mechanism of LQTS related CaM mutation E141G interfering with Ca1.2 channels function through its C-lobe.
J Physiol Biochem
December 2024
Department of Pharmaceutical Toxicology, School of Pharmacy, China Medical University, Shenyang, 110122, China.
Mutations in the CALM1-3 genes, which encode calmodulin (CaM), have been reported in clinical cases of long QT syndrome (LQTS). Specifically, the CaM mutant E141G (CaM) in the variant CALM1 gene has been identified as a causative factor in LQTS. This mutation disrupts the normal Ca-dependent inactivation (CDI) function of Ca1.
View Article and Find Full Text PDFImmunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement.
Leukemia
December 2024
Division of Hematology, Department of Translational Medicine, Università del Piemonte Orientale, Novara, Italy.
The mutational status of immunoglobulin (IG) light chain genes in chronic lymphocytic leukemia (CLL) and its clinical impact have not been extensively studied. To assess their prognostic significance, the IG light chain gene repertoire in CLL patients has been evaluated using a training-validation approach. In the training cohort (N = 573 CLL), 92.
View Article and Find Full Text PDFSingle-cell analysis of a bi-clonal chronic lymphocytic leukemia reveals two clones with distinct gene expression pattern.
Leuk Lymphoma
December 2024
Institute of Cell Biology (Cancer Research), Medical Faculty, University of Duisburg-Essen, Essen, Germany.
Dual productive B-cell receptor (BCR) rearrangements have been repeatedly reported for chronic lymphocytic leukemia (CLL), but the standard population-based PCR analyses cannot distinguish whether these are bi-clonal CLL, or a monoclonal CLL with bi-allelic productive rearrangements. We investigated CLL cells by combined single-cell RNA and BCR sequencing. We identified two CLL clones using different immunoglobulin (Ig) heavy-chain V region genes (IGHV) genes and distinct Ig λ light chains.
View Article and Find Full Text PDFJCO SEQUOIA (ClinicalTrials.gov identifier: NCT03336333) is a phase III, randomized, open-label trial that compared the oral Bruton tyrosine kinase inhibitor zanubrutinib to bendamustine plus rituximab (BR) in treatment-naïve patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). The initial prespecified analysis (median follow-up, 26.
View Article and Find Full Text PDFIncreased c-MYC Expression Associated with Active IGH Locus Rearrangement: An Emerging Role for c-MYC in Chronic Lymphocytic Leukemia.
Cancers (Basel)
November 2024
Centre National de la Recherche Scientifique (CNRS), Unité Mixte de Recherche (UMR) 7276/INSERM U1262, Université de Limoges, 87000 Limoges, France.
Article Synopsis
- * Its overexpression is particularly linked to CLL cases with unmutated immunoglobulin heavy chain variable (IGHV) genes, causing significant DNA damage and contributing to a more aggressive disease.
- * The review emphasizes c-MYC's dual role in promoting rapid cell proliferation and driving genetic recombination, suggesting it could be a promising target for new therapeutic strategies in CLL.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!